Stockscreener 앱 받기
1.98
1.02%
0.02
시간 외 거래:
2.05
0.07
+3.54%
Nls Pharmaceutics Ltd 주식(NLSP)의 최신 뉴스
NLS Pharmaceutics Submits Research Abstracts to ASCP 2025 - TipRanks
NLS Pharmaceutics Launches Preclinical Program for Fentanyl Dependence Treatment - TipRanks
NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence - Marketscreener.com
NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence - Benzinga
NLSP Stock Touches 52-Week Low at $1.73 Amid Steep Annual Decline - MSN
NLS Pharmaceutics and Kadimastem Announce Initial Closing of $500,000 Fundraising Effort for Merger - HPBL
NLS Pharmaceutics and Kadimastem Move Forward with Merger to Create Nasdaq-Traded Biotechnology Company - HPBL
NLS Pharmaceutics and Kadimastem Merger & Financing Update – Market - HPBL
Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS - The Malaysian Reserve
Kadimastem Calls for a Special General Meeting of Shareholders t - GuruFocus.com
NLS Pharmaceutics and Kadimastem Move Toward Merger Approval - TipRanks
NLS Pharmaceutics Completes Initial $500K Financing to Advance Kadimastem Merger - Sleep Review
NLS Pharmaceutics and Kadimastem Advance Merger Plans with $500,000 Fundraising - Yahoo Finance
NLS Pharmaceutics Announces Extraordinary Shareholders’ Meeting Results – Market - HPBL
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market S - The Malaysian Reserve
NLS Pharmaceutics Secures Premium-Priced $500K Investment, Advances Kadimastem Merger Plans - StockTitan
Head-To-Head Analysis: Atossa Therapeutics (NASDAQ:ATOS) & NLS Pharmaceutics (NASDAQ:NLSP) - Defense World
NLS Pharmaceutics Shareholders Approve Meeting Agenda - TipRanks
Merger Between NLS Pharmaceutics and Kadimastem Advances with SEC Filing - Sleep Review
What's Going On With NLS Pharmaceuticals Stock Monday? - Benzinga
NLS Pharmaceutics and Kadimastem Move Forward with Merger Plans - TipRanks
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger - IT News Online
NLS Pharmaceutics and Kadimastem Advance Merger Plans with SEC Registration for CNS Drug Development - StockTitan
NLS Pharmaceutics Calls Extraordinary Meeting for Major Capital Restructuring - TipRanks
NLS Pharmaceutics and Kadimastem eye January merger - Investing.com
NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment - AccessWire
NLSP Stock Hits 52-Week Low at $1.74 Amid Steep Annual Decline By Investing.com - Investing.com South Africa
NLS Pharmaceutics Advances Revolutionary Type 1 Diabetes Treatment, Seeks FDA Pre-IND Meeting - StockTitan
NLSP Stock Hits 52-Week Low at $1.74 Amid Steep Annual Decline - Investing.com India
NLS Pharmaceutics expects to close Kadimastem merger by end of January - Yahoo Finance
NLSP stock touches 52-week low at $1.81 amid market challenges - Investing.com Nigeria
NLS Pharmaceutics advances in narcolepsy treatment research By Investing.com - Investing.com Nigeria
NLS CEO Highlights Progress on Dual Orexin Agonist Platform and Upcoming Merger - Sleep Review
NLS Pharmaceutics Advances DOXA Platform Amid Merger Plans - TipRanks
NLS Pharmaceutics advances in narcolepsy treatment research - Investing.com India
NLS Pharmaceutics CEO Issues Letter to Shareholders - AccessWire
NLS Pharmaceutics Secures $4.2M Funding, Reports Breakthrough in Narcolepsy Treatment Development - StockTitan
NLS Pharmaceutics AG announced that it expects to receive $0.999998 million in funding - Marketscreener.com
5.49%
0.79%
자본화:
|
볼륨(24시간):